| Balance Sheets | 2026-03-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 160,575 | |||
| Marketable securities | 356,066 | |||
| Restricted cash and cash equivalents (vie) | 0 | |||
| Prepaid expenses and other current assets | 18,749 | |||
| Total current assets | 535,390 | |||
| Total property and equipment | 79,367 | |||
| Less accumulated depreciation | 51,530 | |||
| Property and equipment, net | 27,837 | |||
| Operating lease right-of-use assets | 57,765 | |||
| Other assets | 4,745 | |||
| Total assets | 625,737 | |||
| Accounts payable | 7,617 | |||
| Accrued expenses and other current liabilities | 19,267 | |||
| Deferred revenue - current | 17,244 | |||
| Current portion of finance lease liabilities | 3,883 | |||
| Operating lease liabilities - current | 10,378 | |||
| Total current liabilities | 58,389 | |||
| Warrant to purchase convertible preferred stock | 0 | |||
| Finance lease liabilities, net of current portion | 2,221 | |||
| Deferred revenue - non-current | 1,238 | |||
| Operating lease liabilities - non-current | 49,088 | |||
| Other long term liabilities | 0 | |||
| Total liabilities | 110,936 | |||
| Convertible preferred stock | 0 | |||
| Non-controlling interest | 0 | |||
| Common stock, 0.001 par value 500,000,000 and 200,456,735 shares authorized as of march 31, 2026 and december 31, 2025 respectively 128,192,522 and 33,116,957 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 128 | |||
| Additional paid-in capital | 1,252,388 | |||
| Accumulated other comprehensive income | 24 | |||
| Accumulated deficit | -737,739 | |||
| Total stockholders' equity (deficit) | 514,801 | |||
| Total liabilities, convertible preferred stock, non-controlling interests and stockholders' equity (deficit) | 625,737 | |||
Generate Biomedicines, Inc. (GENB)
Generate Biomedicines, Inc. (GENB)